On August 1, 2018 PepVax, Inc., an early-stage biotechnology company, reported the launch of its novel SMARTmid platform for drug delivery of nucleic acid and amino acid-based drugs and cell therapies in pre-clinical development (Press release, PepVax, AUG 1, 2018, View Source [SID1234630790]). With manufacturing and delivery of immunotherapies, cell therapies, and gene therapies getting increasingly complicated and expensive at scale-up, the SMARTmid platform offers a unique solution with our "Trojan Horse" approach to use the patient’s own cells to manufacture the required proteins, T-cells and nucleic acids in vivo for cancers, infectious and genetic diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Learn more about PepVax here – View Source
The Perfect Solution for Researchers and Early-Stage Biotechnology Companies
Our SMARTmid vector design is our fully synthetic method for producing plasmid vector particles for mammalian cell transduction and is a powerful template in which to build a drug delivery and immuno-adjuvant platform. DNA-based delivery can directly enhance expression levels and enable easy manufacturing of protein-, DNA- and RNA-based treatments in vivo. Moreover, SMARTmid can be used as an immuno-adjuvant to enhance already developed drugs to work more effectively in patients requiring a strong immune response, like checkpoint inhibitors and CAR-T treatments. SMARTmid can also be used as a diagnostic tool for certain cancers and infectious diseases.
Efficiency and Simplicity That Just Works
"Delivering drugs has always been a challenge for drug developers," said Mahesh Narayanan, CEO of PepVax. "Researchers and research companies looking to deliver their biologics intramuscularly or intravenously can use our SMARTmid platform to produce their drugs inside the patient or deliver it without worrying about degeneration or decreased potency."
Focused on Continued Innovation
PepVax is looking to license SMARTmid to established biopharmaceutical companies that are looking for efficient drug delivery in patients as well as developing novel cancer and infectious disease therapeutics. The Company is also looking to enter into research agreements with academia.